头颈肿瘤免疫相关基因突变分析

注册号:

Registration number:

ChiCTR2500104117 

最近更新日期:

Date of Last Refreshed on:

2025-06-11 10:36:56 

注册时间:

Date of Registration:

2025-06-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

头颈肿瘤免疫相关基因突变分析

Public title:

Genetic mutations associated with head and neck tumor immunity (CPS/TMB) were retrospectively analyzed based on second-generation sequencing

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于二代测序回顾性分析与头颈肿瘤免疫(CPS/TMB)相关的基因突变

Scientific title:

Genetic mutations associated with head and neck tumor immunity (CPS/TMB) were retrospectively analyzed based on second-generation sequencing

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

黄永胜 

研究负责人:

黄永胜 

Applicant:

Yongsheng Huang 

Study leader:

Yongsheng Huang 

申请注册联系人电话:

Applicant telephone:

+86 15914216989

研究负责人电话:

Study leader's
telephone:

+86 20 34071966

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

huangysh65@mail.sysu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

huangysh65@mail.sysu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广州市海珠区盈丰路33号

研究负责人通讯地址:

广州市越秀区沿江西路107号

Applicant address:

33 Yingfeng Road, Haizhu District, Guangzhou

Study leader's address:

No. 107 Yanjiang West Road, Yuexiu District, Guangzhou

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中山大学孙逸仙纪念医院

Applicant's institution:

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

研究负责人所在单位:

中山大学孙逸仙纪念医院

Affiliation of the Leader:

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SYSKY-2025-063-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中山大学孙逸仙纪念医院医学伦理委员会(第二)

Name of the ethic committee:

Medical Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-02-14 00:00:00

伦理委员会联系人:

区柳珊

Contact Name of the ethic committee:

Qu Liushan

伦理委员会联系地址:

广州市越秀区沿江西路107号

Contact Address of the ethic committee:

No. 107 Yanjiang West Road, Yuexiu District, Guangzhou

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 81332587

伦理委员会联系人邮箱:

Contact email of the ethic committee:

liushan3219@163.com

研究实施负责(组长)单位:

中山大学孙逸仙纪念医院

Primary sponsor:

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

研究实施负责(组长)单位地址:

广州市越秀区沿江西路107号

Primary sponsor's address:

No. 107 Yanjiang West Road, Yuexiu District, Guangzhou

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

中山大学孙逸仙纪念医院

具体地址:

广州市越秀区沿江西路107号

Institution
hospital:

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Address:

No. 107 Yanjiang West Road, Yuexiu District, Guangzhou

经费或物资来源:

自筹

Source(s) of funding:

NA

研究疾病:

头颈肿瘤  

Target disease:

Head and neck tumors

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

本研究拟通过回顾性分析头颈肿瘤患者基因检测结果,分析基因突变与CPS和TMB的关系,探索基因突变对患者免疫治疗的影响。  

Objectives of Study:

This study intends to retrospectively analyze the genetic test results of patients with head and neck tumors and analyze the relationship between gene mutation and CPS and TMB, which explore the influence of gene mutation on patients' immunotherapy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.非实体瘤:血液系统肿瘤和淋巴瘤;
2.未进行NGS检测或NGS检测质控不合格;
3.临床数据缺失,如免疫组化、药物治疗和肿瘤影像学等。

Exclusion criteria:

1.Non-solid tumors: hematological tumors and lymphomas;
2.No NGS test or NGS test quality control fails;
3.Lack of clinical data, such as immunohistochemistry, drug therapy and tumor imaging.

研究实施时间:

Study execute time:

From 2025-01-15 00:00:00 To 2027-02-15 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-06-12 00:00:00 To 2026-02-15 00:00:00

干预措施:

Interventions:

组别:

CPS阳性(或TMB-H)

样本量:

200

Group:

CPS positive(or TMB-H)

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

中山大学孙逸仙纪念医院 

单位级别:

三级甲等 

Institution
hospital:

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

CPS评分

指标类型:

主要指标

Outcome:

CPS score

Type:

Primary indicator

测量时间点:

病理诊断后

测量方法:

基因检测

Measure time point of outcome:

Postpathological diagnosis

Measure method:

Genetic testing

指标中文名:

TMB

指标类型:

主要指标

Outcome:

TMB

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据收集采用电子数据记录和病例报告表的形式进行。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data were collected in the form of electronic data records and case reports.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-06-11 10:36:43